Contrasting the academic and nonacademic hepatology practice settings
AASLD LiverLearning®, Coleman Smith, 190386
Pangenotypic regimens and the next generation hepatitis C virus therapy
AASLD LiverLearning®, Nancy Reau, 190387
Putting it all together: Noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in adults and children
AASLD LiverLearning®, Naim Alkhouri, 190388
Transplantation for acute alcoholic hepatitis
AASLD LiverLearning®, Patrizia Burra, 190389
Developing clinical research in a clinical hepatology practice
AASLD LiverLearning®, Oren Fix, 190390
Antifibrotic therapies in liver disease: Ready for primetime?
AASLD LiverLearning®, David Rudnick, 190391
Noninvasive diagnosis of liver fibrosis in adults
AASLD LiverLearning®, Sumeet Asrani, 190368
Looking after young people with liver conditions: Understanding chronic illness management in the context of adolescent development
AASLD LiverLearning®, Alison Darcy, 190369
Resistance testing: Interpretation and incorporation into HCV treatment algorithms
AASLD LiverLearning®, Jordan Feld, 190370
Hyponatremia in the perioperative period: When and how to correct
AASLD LiverLearning®, Michael Leise, 190371
Update on primary sclerosing cholangitis
AASLD LiverLearning®, Roger W.G. Chapman, 190372
Noninvasive diagnosis of liver fibrosis in adults
AASLD LiverLearning®, Sumeet Asrani, 190380
Looking after young people with liver conditions: Understanding chronic illness management in the context of adolescent development
AASLD LiverLearning®, Alison Darcy, 190381
Resistance testing: Interpretation and incorporation into HCV treatment algorithms
AASLD LiverLearning®, Jordan Feld, 190382
Hyponatremia in the perioperative period: When and how to correct
AASLD LiverLearning®, Michael Leise, 190383
Update on primary sclerosing cholangitis
AASLD LiverLearning®, Roger W.G. Chapman, 190384
Treatment of HCV in persons who inject drugs: Treatment as prevention
AASLD LiverLearning®, Jason Grebely, 190356
Managing the patient with acute liver failure
AASLD LiverLearning®, Constantine Karvellas, 190357
Hepatic fibrosis in children and adults
AASLD LiverLearning®, Rebecca Wells, 190358
Transplanting patients with active bacterial infection
AASLD LiverLearning®, Elizabeth C. Verna, 190359
Acute on chronic liver failure
AASLD LiverLearning®, Patrick Kamath, 190360
Biomarkers and imaging studies to predict portal hypertension and varices
AASLD LiverLearning®, Christine Lee, 190361
Treatment of HCV in persons who inject drugs: Treatment as prevention
AASLD LiverLearning®, Jason Grebely, 190362
Managing the patient with acute liver failure
AASLD LiverLearning®, Constantine Karvellas, 190363
Hepatic fibrosis in children and adults
AASLD LiverLearning®, Rebecca Wells, 190364
Transplanting patients with active bacterial infection
AASLD LiverLearning®, Elizabeth C. Verna, 190365
Acute on chronic liver failure
AASLD LiverLearning®, Patrick Kamath, 190366
Biomarkers and imaging studies to predict portal hypertension and varices
AASLD LiverLearning®, Christine Lee, 190367
Treatment of HCV in persons who inject drugs: Treatment as prevention
AASLD LiverLearning®, Jason Grebely, 190374
Managing the patient with acute liver failure
AASLD LiverLearning®, Constantine Karvellas, 190375
Hepatic fibrosis in children and adults
AASLD LiverLearning®, Rebecca Wells, 190376
Transplanting patients with active bacterial infection
AASLD LiverLearning®, Elizabeth C. Verna, 190377
Acute on chronic liver failure
AASLD LiverLearning®, Patrick Kamath, 190378
Biomarkers and imaging studies to predict portal hypertension and varices
AASLD LiverLearning®, Christine Lee, 190379
Module 1: NAFLD - Diagnosis and Identification of Those at Risk of Disease Progression
AASLD LiverLearning®, Mary Rinella, 175468
Module 2: Pathogenesis of Non-alcoholic Steatohepatitis
AASLD LiverLearning®, Arun Sanyal, 175469
Module 9: Emerging Treatments for Non-Alcoholic Steatohepatitis
AASLD LiverLearning®, Stephen A. Harrison, 175470
Non-Alcoholic Fatty Liver Disease & Non-Alcoholic Steatohepatitis
AASLD LiverLearning®, AASLD, 175471
Module 6: Bariatric Surgery: Is the Cure for NASH in the OR?
AASLD LiverLearning®, Philippe MATHURIN, 175078
Module 4: Lifestyle Interventions: Setting Goals and Recommendations
AASLD LiverLearning®, Brent Tetri, 175077
Module 3: Non-Invasive Determination of Advanced Disease in NAFLD
AASLD LiverLearning®, Leon Adams, 174314
Closing Remarks
AASLD LiverLearning®, Zobair Younossi, 170278
Summary of the Meeting: What to Do Next?
AASLD LiverLearning®, Keith Lindor, 170277
Emerging Therapy for NASH: Antifibrotics
AASLD LiverLearning®, Scott Friedman, 169510
Emerging Therapy for NASH: Non-antifibrotics
AASLD LiverLearning®, Stephen Harrison, 169509
The Current Medical Treatment for Patients with NASH
AASLD LiverLearning®, Manal Abdelmalek, 169508
Weight Loss and Exercise in NAFLD
AASLD LiverLearning®, Jacob George, 169507
What Are the Best Endpoints for the Clinical Trials of NASH: Investigator and Regulatory Perspective
AASLD LiverLearning®, Kris Kowdley, 169506
Serum Fibrosis Markers in NASH
AASLD LiverLearning®, Quentin Mark Anstee, 169505
Noninvasive Biomarkers in NASH
AASLD LiverLearning®, Naga Chalasani, 169504
Role of Histopathology in the Clinical Research and Clinical Management of Patients with NAFLD
AASLD LiverLearning®, Zachary Goodman, 169502
ETC 2017 Course Syllabus
AASLD LiverLearning®, AASLD, 183936
The comparative effect of liraglutide, elafibranor and obeticholic acid on NAFLD Activity Score and Fibrosis Stage in a diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitis
AASLD LiverLearning®, Michael Feigh, 170270
VLX103, a New Hepatoselective Investigational Drug Targeting the LPS-TLR4 Pathway in Non-Alcoholic Liver Disease
AASLD LiverLearning®, Patrick Colin, 170269
Impact of a Structured Exercise, Nutrition and Patient Education Program on Short Term Outcomes in Patients with Non-alcoholic Fatty Liver Disease
AASLD LiverLearning®, Monica Konerman, 170268
Predicting the degree of liver-biopsy-confirmes steatosis and fibrosis using transient elastography and magnetic resonance imaging-based techniques in adult patients with suspected non-alcoholic fatty liver disease
AASLD LiverLearning®, Stephen Harrison, 170267
The Association of Histologic Activity with Long Term Outcomes of Patients with Non-alcoholic Fatty Liver Disease
AASLD LiverLearning®, Maria Stepanova, 170266
Steatosis, Portal Inflammation and Fibrosis are More Advanced in Younger Children with Non-Alcoholic Fatty Liver Disease (NAFLD)
AASLD LiverLearning®, Reham Abdou, 170265
NASH and Bariatric Surgery
AASLD LiverLearning®, Philippe MATHURIN, 169500
Nonalcoholic Fatty Liver Disease in Children: Not a Tiny Matter
AASLD LiverLearning®, Joel Lavine, 169499
Racial and Ethnic Differences in Nonalcoholic Fatty Liver Disease
AASLD LiverLearning®, Arun Sanyal, 169498
Fibrogenesis of NASH: What Is Different About It?
AASLD LiverLearning®, Scott Friedman, 169496
NAFLD and Microbiome
AASLD LiverLearning®, Kathleen Corey, 169495
The Role of Mitochondria and Endoplasmic Reticulum in NASH Pathogenesis
AASLD LiverLearning®, Stephen Caldwell, 169493
Session II: Metabolic Syndrome and NASH : Q&A
AASLD LiverLearning®, Session Speakers, 170256
Cardiovascular Diseases and NAFLD
AASLD LiverLearning®, Francesco Negro, 169492
Lipid Abnormalities in NAFLD
AASLD LiverLearning®, lawrence serfaty, 169491
Insulin Resistance in NAFLD
AASLD LiverLearning®, Brent Tetri, 169490
Is MS the Consequence or Precursor of NASH?
AASLD LiverLearning®, Giulio Marchesini, 169489
Q&A
AASLD LiverLearning®, Session Speakers, 169830
Will the Epidemic of NAFLD Be Responsible for the Future Burden of HCC?
AASLD LiverLearning®, Elisabetta Bugianesi, 169488
Long Term Outcomes: Mortality and Causes of Death in NAFLD
AASLD LiverLearning®, Mary Rinella, 169487
Clinical, Epidemiologic, Patient-Reported and Economic Burden of NAFLD
AASLD LiverLearning®, Zobair Younossi, 169486
Welcome and Opening Remarks
AASLD LiverLearning®, Zobair Younossi, 169828
Welcome and Opening Remarks
AASLD LiverLearning®, Keith Lindor, 169829
Controversy Regarding HCV Treatment and HCC Recurrence
AASLD LiverLearning®, Amit Singal, 167450
Laboratory‐based biomarkers to improve causality assessment in drug‐induced liver injury
AASLD LiverLearning®, Daniel Antoine, 171991
The role of the hepatopathologist in the assessment of drug‐induced liver injury
AASLD LiverLearning®, David Kleiner, 171992
Novel treatments targeting metabolic and signaling mechanisms in primary biliary cholangitis
AASLD LiverLearning®, Michael Trauner, 171993
What can we learn from other clinical settings on the influence of the gut microbiome on the brain?
AASLD LiverLearning®, Eamonn M. M. Quigley, 171994
Introduction and setting the scene: New nomenclature of hepatic encephalopathy and American Association for the Study of Liver Diseases/European Association for the Study of the Liver guidelines
AASLD LiverLearning®, Jasmohan Bajaj, 171995
Overview of causality assessment in drug‐induced liver injury
AASLD LiverLearning®, Paul Hayashi, 171996
Portal Vein Thrombosis in Cirrhosis: Causes and Consequences
AASLD LiverLearning®, Stephen Caldwell and Juan C. Garcia-Pagan, 167449
Thrombosis and coagulopathy in the liver transplant candidate and recipient
AASLD LiverLearning®, R. Todd Stravitz, 169134
The highly sensitized, high MELD, simultaneous liver‐kidney or status 1A heart‐liver transplant candidate
AASLD LiverLearning®, Timucin Taner, 169135
Genetics in liver diseases: From diagnostics to precise therapy
AASLD LiverLearning®, Frank Lammert, 169136
Developing a liver cancer program in the nonacademic medical center
AASLD LiverLearning®, Kent Benner, 169137
Changes in united network for organ sharing policy for simultaneous liver‐kidney allocation
AASLD LiverLearning®, David Mulligan, 169138
Elastography to assess the stage of liver fibrosis in children: Concepts, opportunities, and challenges
AASLD LiverLearning®, Claude Sirlin, 169139
Module 5: Comorbidities in NAFLD: Cardiovascular Disease, Sleep Apnea, and Chronic Kidney Disease
AASLD LiverLearning®, Kathleen Corey, 166911
Module 8: Current Pharmacological Treatment Options for Non-Alcoholic Steatohepatitis (NASH)
AASLD LiverLearning®, Dawn Torres, 166127
Module 7: Managing NASH Cirrhosis and Assessment for Liver Transplant
AASLD LiverLearning®, Kymberly Watt, 173365
A framework to determine when liver transplantation is futile
AASLD LiverLearning®, Jennifer Lai, 165947
The changing face of hepatic encephalopathy: A projection for the next 5 years
AASLD LiverLearning®, Debbie L Shawcross, 165948
Treatment of chronic cholestasis: What we know and what we will know?
AASLD LiverLearning®, James Boyer, 165949
Managing encephalopathy in the outpatient setting
AASLD LiverLearning®, Radha Dhiman, 165950
Mechanisms of portal hypertension: Bench to bedside
AASLD LiverLearning®, Jordi Gracia‐Sancho, 165951
Novel approaches to the treatment of biliary atresia
AASLD LiverLearning®, Jorge A. Bezerra, 165952
The scope of hepatology practice outside the traditional academic medical center
AASLD LiverLearning®, Marcelo Kugelmas, 164852
Novel treatments in primary sclerosing cholangitis
AASLD LiverLearning®, Keith Lindor, 164853